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Emphysema is an intractable pulmonary disease characterized by an inflammatory
process of the airways and lung parenchyma and ongoing remodeling process in an
attempt to restore lung structure. There is no effective drug therapy that regenerates
lung tissue or prevents the progression of emphysema; current treatment is aimed
at symptomatic relief. We hypothesized that LASSBio-596, a molecule with potent
anti-inflammatory and immunomodulatory effects, might reduce pulmonary inflammation
and remodeling and thus improve lung function in experimental emphysema.
Emphysema was induced in BALB/c mice by intratracheal administration of porcine
pancreatic elastase (0.1 IU) once weekly during 4 weeks. A control group received
saline using the same protocol. After the last instillation of saline or elastase, dimethyl
sulfoxide, or LASSBio-596 were administered intraperitoneally, once daily for 8 days.
After 24 h, in elastase-induced emphysema animals, LASSBio-596 yielded: (1) decreased
mean linear intercept, hyperinflation and collagen fiber content, (2) increased elastic fiber
content, (3) reduced number of M1macrophages, (4) decreased tumor necrosis factor-α,
interleukin-1β, interleukin-6, and transforming growth factor-β protein levels in lung tissue,
and increased vascular endothelial growth factor. These changes resulted in increased
static lung elastance. In conclusion, LASSBio-596 therapy reduced lung inflammation,
airspace enlargement, and small airway wall remodeling, thus improving lung function, in
this animal model of elastase-induced emphysema.
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Introduction
Emphysema, defined as irreversible destruction of the alveoli, is associated with an inflammatory
process of the airways and lung parenchyma (Newell, 2008) and an ongoing remodeling
process in an attempt to restore lung structure (Papaioannou et al., 2010). Decades of research
have still not resulted in an effective treatment other than cessation of cigarette smoking,
a highly addictive behavior. Strategies focusing on development of anti-inflammatory drugs,
such as antagonists of cytokines, including TNF-α (Dentener et al., 2008) and interleukin
(IL)-8 (Mahler et al., 2004), have proved disappointing, and current treatment is aimed at
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symptomatic relief. One potential therapeutic approach for
emphysema is decreasing the chronic inflammation and
fibrogenesis associated with induction of lung repair and
regeneration.
LASSBio-596 is an achiral molecule in the carbamoyl-benzoic
acid class that was designed as a symbiotic agent from the
hybridization of prototypes originating from thalidomide,
arylsulfonamide, and sildenafil (Lima et al., 2002; Rocco et al.,
2010). The therapeutic potential of LASSBio-596 has been
studied in experimental models of acute lung inflammation
induced by Escherichia coli lipopolysaccharide (Rocco et al.,
2003), microcystin-LR (Carvalho et al., 2010), and chronic
allergic inflammation (Campos et al., 2006); it has been
found to act mainly on inflammatory processes, improving
pulmonary function. Furthermore, LASSBio-596 is not
associated with relevant side effects, unlike corticosteroids,
which are commonly used in emphysema (Calverley, 2014).
Therefore, we hypothesized that, in an elastase-induced
emphysema model, LASSBio-596 therapy might act on lung
inflammation and remodeling as well as stimulate elastogenesis.
Materials and Methods
This study was approved by the Animal Research Ethics
Committee of the Federal University of Rio de Janeiro Health
Sciences Center (CEUA-CCS-IBCCF 019). All animals received
humane care in compliance with the “Principles of Laboratory
Animal Care” formulated by the National Society for Medical
Research and the “Guide for the Care and Use of Laboratory
Animals” prepared by the U.S. National Academy of Sciences.
Animal Preparation and Experimental Protocol
Thirty-six male BALB/c mice (weight 20–25 g, age 8–10 weeks)
were used in this study. The animals were kept under specific
pathogen-free conditions in the animal care facility of the
Laboratory of Pulmonary Investigation, Federal University of Rio
de Janeiro. All animals were randomly assigned to two groups. In
control (C) animals, saline was instilled intratracheally (50µl),
whereas emphysema (E) mice received porcine pancreatic
elastase (PPE, Sigma Chemical Co., St. Louis, MO, USA) (0.1 UI
in 50µl saline solution) via the same route. Saline and PPE were
injected intratracheally once a week for 4 weeks. For intratracheal
instillation, mice were anesthetized with sevoflurane. Induction
of emphysema was performed according to a previous protocol
established in our laboratory (Cruz et al., 2012). Static lung
elastance (Est,L), mean linear intercept (Lm), and mononuclear
cells and neutrophils (tissue cellularity) were analyzed at day 21
in a total of 12 animals (n = 6/group). The remaining 24 animals
were subjected to the same protocol, but, after day 21, were
further randomized into subgroups to receive DMSO (10mg/kg,
0.02mL, intraperitoneally [i.p.]) or LASSBio-596 (596, 10mg/kg,
0.02mL i.p.) for 8 consecutive days (Figure 1). These animals
were analyzed on day 29.
Lung Mechanics
Twenty-four hours after the last intraperitoneal treatment,
animals were sedated (diazepam 1mg i.p.), anesthetized
(thiopental sodium 20mg/kg i.p.), tracheotomized, paralyzed
(vecuronium bromide 0.005mg/kg i.v.), and ventilated with
a constant flow ventilator (Samay VR15; Universidad de
la Republica, Montevideo, Uruguay) set to the following
parameters: frequency 100 breaths/min, tidal volume (VT)
0.2mL, and fraction of inspired oxygen (FiO2) 0.21. After
neuromuscular blockade, adequate depth of anesthesia was
assessed by evaluating pupil size and reactivity to light (Correa
et al., 2001). The anterior chest wall was surgically removed
and a positive end-expiratory pressure (PEEP) of 2 cm H2O
was applied. After a 10min ventilation period, airflow, volume,
and tracheal pressure (Ptr) were measured. In an open chest
preparation, Ptr reflects transpulmonary pressure (PL). Est,L was
measured by the end-inflation occlusion method (Bates et al.,
1985). All mechanical data were analyzed using the ANADAT
data analysis software (RHT-InfoData, Inc., Montreal, Quebec,
Canada). At the end of the experiments (20min), animals were
euthanized and lungs prepared for histology and protein analysis.
Lung Histology
Immediately after assessment of lung mechanics, a laparotomy
was performed and heparin (1000 IU) was injected into the
inferior vena cava. The trachea was clamped at end-expiration
(2 cm H2O) and the abdominal aorta and vena cava were
sectioned, yielding a massive hemorrhage that quickly killed
the animals. The left lung was then removed, frozen quickly
by immersion in liquid nitrogen, fixed with Carnoy’s solution,
and embedded in paraffin. Three 4-µm-thick slices were cut
from each lung and stained with hematoxylin-eosin for lung
morphometric analysis, Weigert’s resorcin-fuchsin method with
oxidation for quantification of elastic fibers in alveolar septa, or
Sirius red solution for quantification of collagen fibers in alveolar
septa (Fullmer et al., 1974; Montes, 1996). Lung morphometry
analysis was performed using a reticle composed of a grid
with 100 points and 50 lines of known length coupled to
the integrating eyepiece of a conventional light microscope
(Olympus BX51,Olympus Latin America-Inc., Brazil). The
volume fractions of the lung occupied by collapsed alveoli
(alveoli with rough or plicate walls), normal pulmonary areas, or
hyperinflated structures (alveolar ducts, alveolar sacs, or alveoli,
all with maximal chord length in air >120µm) were determined
by the point-counting technique (Weibel, 1990) across 10
random, non-coincident microscopic fields. Briefly, points falling
on collapsed, normal pulmonary areas or hyperinflated structures
were counted and divided by the total number of points in each
microscopic field. Enlargement of air spaces was evaluated using
mean linear intercept measurement (Lm) (Dunnill, 1964). The
number of total cells, neutrophils, and mononuclear cells, as well
as the amount of pulmonary tissue, were also determined by
the point-counting technique across 10 random, non-coincident
microscopic fields at×1000 magnification. Data were reported as
the fraction area of pulmonary tissue.
Collagen and Elastic Fibers Quantification
Collagen (Picrosirius-polarization method) and elastic fibers
were quantified in alveolar septa at ×400 magnification. The
area occupied by fibers was determined by digital densitometric
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FIGURE 1 | Flowchart and timeline of study design. Control (C), four intratracheal administrations of saline; Emphysema (E), four intratracheal administrations of
porcine pancreatic elastase (PPE); DMSO, vehicle (dimethyl sulfoxide)—intraperitoneal treatment with DMSO for 8 days; LASSBio-596, intraperitoneal treatment with
LASSBio-596 for 8 days. All data were analyzed on day 29.
recognition (Image-Pro Plus 7.1 Software, Media Cybernetics—
Silver Spring, MD, USA) and divided by the area of each
studied septum. The results were expressed as the fractional area
occupied by elastic and collagen fibers in the alveolar septa.
Bronchi and blood vessels were excluded from the measurements
to avoid biased results.
Immunohistochemistry for M1 and M2
Macrophages
Immunohistochemical analysis for M1 and M2 macrophages in
lung tissue was performed using inducible nitric oxide synthase
rabbit anti-mouse polyclonal antibody (catalog no. RB-9242,
Thermo Scientific) and arginase-1 rabbit anti-mouse polyclonal
antibody (catalog no. SC-20150, Santa Cruz Biotechnology),
respectively. Paraffin-embedded tissue sections (4µm) were
dewaxed, rehydrated, and underwent heat-mediated antigen
retrieval. Antibodies were detected with a secondary antibody
labeled with peroxidase from Nichirei Biosciences (Tokyo,
Japan) (Histofine mouse MAX PO anti-rabbit), followed by the
chromogen substrate diaminobenzidine (liquid DAB; catalog no.
K3468, DakoCytomation, USA). Slides were counterstained with
hematoxylin-eosin. Analysis was performed in 30 images, at
magnification ×400, under a light microscope (Olympus BX51,
Olympus Latin America-Inc., Brazil). The areas occupied by
cells with positive staining for the phenotype marker were then
measured and divided by tissue area using Image-Pro Plus 6.3
for Windows software (Media Cybernetics, Silver Spring, MD,
USA) and expressed as fraction area occupied by positive cells
(Lopes-Pacheco et al., 2013).
Enzyme-linked Immunosorbent Assay
Central slices of right lung were cut and flash-frozen. IL-
1β, tumor necrosis factor (TNF)-α, IL-6, tumor growth factor
(TGF)-β, and vascular endothelial growth factor (VEGF) were
quantified by enzyme-linked immunosorbent assay (ELISA,
Duo Set; R & D Systems, Minneapolis, USA), according to
manufacturer protocols.
Statistical Analysis
Data were tested for normality using the Kolmogorov-Smirnov
test with Lilliefors correction, whereas the Levene median test
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was used to evaluate the homogeneity of variances. Student’s
t-test was used to compare differences between control and
emphysema animals at day 21. Two-Way ANOVA followed
by Tukey’s test was used to compare control and emphysema
groups treated with DMSO or LASSBio-596. For non-parametric
data, One-Way ANOVA on ranks followed by Dunn’s post-hoc
test was selected. The significance level was always set at 5%.
Parametric data were expressed as mean ± standard deviation
(SD), while non-parametric data were expressed as median
(interquartile range). All tests were performed in the GraphPad
Prism statistical software (version 5.00, GraphPad Software, La
Jolla, California, USA).
Results
At day 21, Est,L was significantly lower in E compared to C
animals (Figure 2A). Histological analysis revealed a higher Lm
(Figure 2B) as well as a greater number of mononuclear cells and
neutrophils in lung tissue in E than C (Figure 2C). Figure 2D
shows destruction of alveolar septa (black arrow), associated with
increased cell infiltration.
After confirmation of emphysema features on day 21, mice
received DMSO or LASSBio-596 and lung mechanics were
analyzed at day 29. Est,L was lower in the E-DMSO group
compared to C-DMSO. E-LASSBio-596 animals exhibited higher
static lung elastance compared to E-DMSO, but did not achieve
control (C) values (Figure 3).
E-DMSO animals exhibited higher Lm compared to
C-DMSO, and this parameter was reduced in E-LASSBio-596
(Figure 4). Additionally, E-DMSO animals showed areas of
hyperinflation characteristic of emphysema, which were reduced
after therapy with LASSBio-596 (Table 1). The number of
neutrophils was higher in E-DMSO and E-LASSBio-596 animals
compared to the respective control groups, but no difference
was observed between E-DMSO and E-LASSBio-596. Moreover,
the number of mononuclear cells did not differ among groups
(Table 1). Even though no differences were observed in the
number of mononuclear cells, M1 macrophage subpopulations
increased in E-DMSO compared to C-DMSO. E-LASSBio-596
mice showed a reduction in the percentage of M1 compared to
FIGURE 3 | Static lung elastance (Est,L). Values are means (± SD) of six
animals in each group. C-DMSO: mice received intratracheal saline and were
treated with DMSO. C-LASSBio-596 mice received intratracheal saline and
were treated with LASSBio-596. E-DMSO: mice received intratracheal porcine
pancreatic elastase and were treated with DMSO. E-LASSBio-596: mice
received intratracheal porcine pancreatic elastase and were treated with
LASSBio-596. *Significantly different from C (p < 0.05). #Significantly different
from E-DMSO (p < 0.05).
FIGURE 2 | Static lung elastance (Est,L) (A), mean linear intercept (Lm) (B), mononuclear cells, neutrophils, and total cells in lung tissue (C), and
representative photomicrographs of lung parenchyma stained with hematoxylin-eosin. Note enlargement of alveolar space in the Egroup (arrow) (D).
Presence of pulmonary emphysema on day 21 was analyzed in two groups (C,E). C, mice received intratracheal saline and were analyzed on day 21; E, mice
received intratracheal porcine pancreatic elastase and were analyzed on day 21. *Significantly different from C (p < 0.05).
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FIGURE 4 | Representative photomicrographs of lung parenchyma
stained with hematoxylin-eosin. Note the enlargement of alveolar space in
the E-DMSO group (arrow). C-DMSO: mice received intratracheal saline and
were treated with DMSO. C-LASSBio-596 mice received intratracheal saline
and were treated with LASSBio-596. E-DMSO mice received intratracheal
porcine pancreatic elastase and were treated with DMSO. E-LASSBio-596:
mice received intratracheal porcine pancreatic elastase and were treated with
LASSBio-596. Original magnification: × 200. Bars = 100µm.
TABLE 1 | Lung histology.
Groups C E
DMSO LASSBio- DMSO LASSBio-
596 596
Normal (%) 94.6± 1.7 93.4±1.8 51.4± 19.1* 75.9±6.1*,#
Collapse (%) 5.4± 1.7 6.2±2.0 4.9± 5.9 3.2±1.2
Hyperinflation (%) 0.0± 0.0 0.4±0.8 43.6± 13.8* 21.0±6.2*,#
Mean linear
intercept (Lm)
42.2± 3.8 43.5±5.3 59.4± 7.6* 50.7±6.6*,#
Mononuclear
cells (%)
28.5± 1.6 30.0±1.6 25.7± 1.0 27.3±1.7
Neutrophils (%) 2.9± 0.4 3.0±0.3 5.2± 0.6* 4.8±0.4*
All data were collected in 10 random, non-coincident fields per mice. Values are means (±
SD) of six animals in each group. C-DMSO: mice received intratracheal saline and were
treated with DMSO. C-LASSBio-596 mice received intratracheal saline and were treated
with LASSBio-596. E-DMSO: mice received intratracheal porcine pancreatic elastase and
were treated with DMSO. E-LASSBio-596: mice received intratracheal porcine pancreatic
elastase andwere treated with LASSBio-596. *Significantly different from respective group
C (p < 0.05). #Significantly different from E-DMSO (p<0.05).
E-DMSO (Figure 5A). On the other hand, no differences in M2
subpopulations were observed among groups (Figure 5B).
The content of collagen fibers in E-DMSO mice was higher
compared to C-DMSO. E-LASSBio-596 mice showed a lower
collagen fiber content than E-DMSO (Figure 6). Furthermore,
elastic fiber content was lower in the E-DMSO group compared
to C-DMSO, and higher in E-LASSBio-596 than in E-DMSO
(Figure 7).
The E-DMSO group showed increased levels of TNF-α, IL-1β,
IL-6, TGF-β, and VEGF compared to C-DMSO. E mice treated
with LASSBio-596 showed lower TNF-α, IL-1β, IL-6, and TGF-β
levels compared to E-DMSO (Figures 8A–D). Interestingly,
VEGF levels in E-LASSBio-596 were higher than in the E-DMSO
group (Figure 8E).
Discussion
In a murine model of elastase-induced pulmonary emphysema,
we found that LASSBio-596: (1) improved elastic recoil, as
observed by the decrease in hyperinflation and mean linear
intercept; (2) decreased collagen fiber content and TGF-β levels
in animals with experimental emphysema; (3) despite not acting
on the percentage of total mononuclear cells, blunted the M1
phenotype; (4) reduced levels of TNF-α, IL1-β, IL-6 in lung
tissue; and (5) increased VEGF levels in lung tissue. These results
corroborated our hypothesis that treatment with LASSBio-596
acted on both the inflammatory and fibrogenic responses, as well
as stimulated elastogenesis, leading to beneficial functional effects
in animals with pulmonary emphysema.
Several animal models have been developed in attempts to
reproduce pulmonary emphysema (Antunes and Rocco, 2011;
Kurimoto et al., 2013). The model of multiple intratracheal
instillations of PPE was initially developed by Lüthje et al.
(2009) and modified by our group (Cruz et al., 2012). In
contrast to the classical single-dose protocols of elastase-induced
emphysema (Antunes and Rocco, 2011), which induce only
emphysema-like lesions without systemic or cardiovascular
impairment, the present model results in histological and
ultrastructural lung changes and cardiac impairment that
resemble human emphysema. In the present study, we evaluated
lung morphofunctional changes associated with emphysema
onset and start of therapy. At day 21, static lung elastance (Est,L)
in the E group was reduced, which is one of the main features
of pulmonary emphysema (GOLD, 2015). Interestingly, Est,L
reduced from day 21 to 29, thus suggesting that emphysema
worsens progressively over time. The loss of elastic recoil results
from elastic fiber disruption in lung parenchyma, alveolar septa
destruction (Takahashi et al., 2014) that leads to increased
mean linear intercept (Figure 2B), and heterogeneous alveolar
architecture after elastase instillation (Figure 2D) (Hamakawa
et al., 2011). These lung histological changes were associated
with an abnormal inflammatory response (Newell, 2008). In the
alveolar surface, macrophage activation leads to the release of
several inflammatory mediators and recruitment of neutrophils
to the site of injury. In this line, we found that animals subjected
to elastase instillation had a higher number of neutrophils in lung
tissue (Bezerra et al., 2011).
Several studies have developed new pharmacologic strategies
to mitigate the inflammation or remodeling processes (Churg
et al., 2007; Baila et al., 2012). Despite the results obtained
in animal models, application of these therapies in patients
was associated with only mild improvement and did not
prevent disease progression (Loza et al., 2012; Zuo et al.,
2014). In our study, therapy with LASSBio-596 was started
after identification of emphysema features, thus mimicking
the clinical setting. LASSBio-596 is the result of molecular
hybridization of thalidomide and arylsulfonamide derivatives
(Lima et al., 2002) and has been shown to exert anti-inflammatory
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FIGURE 5 | Immunohistochemical analysis for the M1 (A) and (B) M2 macrophage phenotypes in lung tissue. Values are means (± SD) of six animals in
each group. C-DMSO: mice received intratracheal saline and were treated with DMSO. C-LASSBio-596 mice received intratracheal saline and were treated with
LASSBio-596. E-DMSO: mice received intratracheal porcine pancreatic elastase and were treated with DMSO. E-LASSBio-596: mice received intratracheal porcine
pancreatic elastase and were treated with LASSBio-596. *Significantly different from respective group C (p < 0.05). #Significantly different from E-DMSO (p < 0.05).
FIGURE 6 | Collagen fiber content in lung parenchyma. All data were
collected in 10 random, non-coincident fields per mouse. Values are means (±
SD) of six animals in each group. C-DMSO: mice received intratracheal saline
and were treated with DMSO. C-LASSBio-596 mice received intratracheal
saline and were treated with LASSBio-596. E-DMSO: mice received
intratracheal porcine pancreatic elastase and were treated with DMSO.
E-LASSBio-596: mice received intratracheal porcine pancreatic elastase and
were treated with LASSBio-596. *Significantly different from respective group
C (p < 0.05). #Significantly different from E-DMSO (p < 0.05).
effects in both pulmonary (Rocco et al., 2003; Carvalho et al.,
2010) and non-pulmonary diseases (Ribeiro et al., 2012). Our
study was the first to analyze the effects of LASSBio-596
in elastase-induced emphysema. Emphysema animals treated
with LASSBio-596 showed mild restoration of elastic recoil
and a decreased mean linear intercept. We also observed
reduced fibroproliferation, which may also have contributed
to improvement of lung mechanics and morphometry. These
beneficial effects of LASSBio-596 may be attributed to inhibition
of NOX-2 and NOX-4, which are expressed in endothelial cells,
macrophages, and myofibroblasts, and commonly related to cell
proliferation, migration, and differentiation (van der Vliet, 2008;
Griffith et al., 2009). In this line, even though NOX-2 and NOX-4
were not measured in the present study, LASSBio-596 has been
shown to inhibit their mRNA expressions in hepatic injury after
microcystin-Lr (Zin et al., 2013) and modulate NADPH oxidases,
reducing the remodeling process (Ellmark et al., 2005).
FIGURE 7 | Elastic fiber content in lung parenchyma. All data were
collected in 10 random, non-coincident fields per mouse. Values are means (±
SD) of six animals in each group. C-DMSO: mice received intratracheal saline
and were treated with DMSO. C-LASSBio-596 mice received intratracheal
saline and were treated with LASSBio-596. E-DMSO: mice received
intratracheal porcine pancreatic elastase and were treated with DMSO.
E-LASSBio-596: mice received intratracheal porcine pancreatic elastase and
were treated with LASSBio-596. *Significantly different from respective group
C (p < 0.05).
LASSBio-596 did not alter the number of neutrophils in lung
tissue, which was increased in our emphysema model. Even
though the number of total mononuclear cells was not increased
in lung tissue, we were unable to rule out that these changesmight
have been associated with differences in macrophage phenotypes
(M1 and M2 macrophages) (Kunz et al., 2011). In this context,
macrophage phenotypes in lung parenchyma were investigated.
The classically activated M1 macrophages are associated with
antimicrobial properties and the release of pro-inflammatory
cytokines, whereas the alternatively activated M2 phenotype acts
as an anti-inflammatory profile and contributes to wound healing
(Lopes-Pacheco et al., 2013). In our study, M2 levels did not
differ among groups; however, the levels of M1 macrophages
were higher in E-DMSO compared to C-DMSO group. M1-
derived cytokines, such as TNF-α, IL-1β, and IL-6, also play
a role in the pathogenesis of COPD (Bucchioni et al., 2003;
Sapey et al., 2009). In fact, we observed higher expression of
these inflammatory proteins in E-DMSO compared to C-DMSO
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FIGURE 8 | Levels of tumor necrosis factor (TNF)-α (A), interleukin (IL)-1β (B), IL-6 (C), transforming growth factor (TGF)-β (D) and vascular endothelial
growth factor (VEGF) (E) quantified by ELISA in lung tissue. Values are median (interquartile range) of six animals in each group. C-DMSO: mice received
intratracheal saline and were treated with DMSO. C-LASSBio-596 mice received intratracheal saline and were treated with LASSBio-596. E-DMSO: mice received
intratracheal porcine pancreatic elastase and were treated with DMSO. E-LASSBio-596: mice received intratracheal porcine pancreatic elastase and were treated with
LASSBio-596. *Significantly different from respective group C (p < 0.05). #Significantly different from E-DMSO (p < 0.05).
animals, and treatment with LASSBio-596 reduced M1 levels.
High levels of IL-1β have been observed in bronchoalveolar
lavage fluid both in experimental (Inoue et al., 2010) and in
clinical settings (Ferhani et al., 2010), and may be inversely
related to lung function. Similarly, we observed that LASSBio-
596 reduced IL-1β levels in lung tissue, which were higher in E-
DMSO than in C-DMSO mice. TNF-α is one of the most studied
cytokines in the pathophysiology of COPD, and is associated
with COPD exacerbations (Aaron et al., 2013). In the model
of emphysema used in the present study, LASSBio-596 reduced
TNF-α, which is consistent with previous studies in models of
acute lung injury (Rocco et al., 2003) and asthma (Campos et al.,
2006). IL-6, another mediator associated with worse prognosis in
COPDpatients (Celli et al., 2012; Ferrari et al., 2013), was reduced
after LASSBio-596 therapy in the present study.
Growth factors are polypeptides involved in cellular
transformation during remodeling process in several diseases
(Barnes, 2008). In emphysema, the increase in TGF-β expression
in epithelial cells and fibroblasts resulted in increased production
of collagen and other extracellular matrix proteins (Takizawa
et al., 2001; Takahashi et al., 2014). Similarly, in elastase-
induced emphysema mice in this study, levels of TGF-β, and
collagen fibers were increased, and LASSBio-596 treatment
reduced both. We may hypothesize that LASSBio-596 acts on
fibrogenesis not only by reducing TGF-β but also by decreasing
lung inflammation and, thus, conversion of fibroblasts into
myofibroblasts (Van Linthout et al., 2014). The increase in VEGF
levels in our emphysema model was consistent with previous
clinical investigations (Kranenburg et al., 2005). Previous studies
in our lab have shown that the elastase-induced emphysema
models is associated with pulmonary hypertension (Cruz et al.,
2012), which is in line with enhanced VEGF expression (Tuder
et al., 1994; Shehata et al., 1999). LASSBio-596 resulted in a
further increase in VEGF, thus stimulating angiogenesis in an
attempt to restore endothelial structure and function (Healy
et al., 2000).
In parallel with the intense lung inflammatory process,
emphysema is characterized by alveolar destruction and
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inadequate remodeling of the lung parenchyma (Suki and
Bates, 2011), with both collagen fiber deposition and elastolysis.
The resulting lung mechanical changes, which reduced Est,L,
were very likely due to elastolysis, changes in the function of
collagen fibers, and modifications in collagen organization (Ito
et al., 2005). Emphysematous animals treated with LASSBio-596
showed an increase in elastic fiber content and a reduction in the
amount of collagen fibers, in agreement with other experimental
models of acute lung injury (Rocco et al., 2003) and asthma
(Campos et al., 2006).
Some limitations of this study should be considered: (1)
emphysema was induced by elastase, and the pathways involved
in elastase induction differ from those occurring in smoke-
induced emphysema, which may lead to differential responses
to LASSBio-596; (2) a decrease in M1 macrophage levels was
observed in emphysema group animals treated with LASSBio-
596. Further studies should be performed to evaluate the role of
M1 macrophages in the immunomodulating effect of LASSBio-
596, e.g., by depletion of M1 macrophages in the mouse lung.
Additionally, the role of LASSBio-596 needs to be analyzed in
other cells, such as epithelial cells, endothelial cells, or fibroblasts;
and (3) only a few specific cytokines and growth factors were
evaluated; a wider range of mediators should be analyzed to
provide a more complete understanding of the mechanisms
associated with inflammation, apoptosis, and/or oxidative stress.
In conclusion, LASSBio-596 reduced lung inflammation and
remodeling, improving lung function and structure, in an
experimental model of elastase-induced pulmonary emphysema.
These findings might be associated with the anti-inflammatory
properties of LASSBio-596, modulating the M1 macrophage
phenotype, and the release of cytokines and growth factors
involved in the pathogenesis of emphysema. Nevertheless,
further experimental studies are required to evaluate different
mechanisms of LASSBio-596 in emphysema and thus reach
clinical application.
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